Linagliptin 1a Pharma (Linagliptin)

Linagliptin selectively blocks the DPP‑4 enzyme, which results in higher levels of the incretin hormones GLP‑1 and GIP. These hormones increase insulin secretion and decrease glucagon release in a glucose‑dependent manner, helping to lower blood sugar levels.

The prescribed dose of Linagliptin 1a Pharma is determined by the treating physician based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the exact dosing instructions provided by their healthcare professional.

Safety of linagliptin in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and only under the guidance of a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin belongs to the DPP‑4 inhibitor class, which differs from sulfonylureas, metformin, or SGLT2 inhibitors. DPP‑4 inhibitors work by enhancing endogenous incretin activity and have a low risk of hypoglycaemia when used alone, whereas sulfonylureas directly stimulate insulin release and may cause more frequent low‑blood‑sugar episodes.

Linagliptin 1a Pharma tablets should be stored at room temperature, below 25 °C, in the original packaging. Protect them from moisture and direct light to maintain product stability throughout its shelf life.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow any specific instructions given by their prescriber.

Serious adverse events, although rare, include pancreatitis, severe allergic reactions such as anaphylaxis, and autoimmune skin conditions like bullous pemphigoid. Any signs of severe abdominal pain, rash, or breathing difficulties should prompt immediate medical evaluation.

Linagliptin is contraindicated in patients with a known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for individuals with a history of pancreatitis or severe renal/hepatic impairment, and it should be avoided in pregnancy unless clearly indicated.